084 Citation: Magalhães JL, Viçosa AL, De Barros GR (2020) Technology transfer model for the formulation stage in biological products for public health Arch Community Med Public Health 6(1): 084-087. DOI: https://dx.doi.org/10.17352/2455-5479.000084 https://dx.doi.org/10.17352/acmph DOI: 2455-5479 ISSN: MEDICAL GROUP Abstract Technology transfer is a tool used to absorb knowledge and technology, in addition to increasing a country’s technological innovation. In the health sector, it is no different, especially in times of outbreaks, epidemics and global pandemic. Therefore, tools that assist in the creation of public policies contribute to the research, development and innovation of new technologies to produce vaccines and medicines. Thus, it proposes a universal technology transfer model based on International guides from the World Health Organization, Parenteral Drugs Association and the International Society of Pharmaceutical Engineering. It was concluded that the model ensures reliability between the parties and promotes a dynamic and rapid methodology for application in public health in the country. Mini Review Technology transfer model for the formulation stage in biological products for public health Jorge L Magalhães 1,2 *, Alessandra L Viçosa 3 , Giselle Ribeiro de Barros 4 1 Technological Innovation Center and Professional Postgraduate Program in Management, Research and Development in the Pharmaceutical Industry, Institute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil 2 Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisboa, Portugal. 3 Department of Galenic Innovation, Deputy Direction of Education, Research and Innovation, Institute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil 4 Final Processing Department, Biomanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil Received: 04 May, 2020 Accepted: 25 May, 2020 Published: 26 May, 2020 *Corresponding author: Jorge L Magalhães, Technological Innovation Center and Professional Postgraduate Program in Management, Research and Development in the Pharmaceutical Industry, Institute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil, E-mail: Keywords: Public Health; Technology transfer model; Public private partnership; Medicines https://www.peertechz.com with its documentation and professional expertise between development and manufacturing or between manufacturing sites” [4]. According to Mohite and Sangle [3], it has two sources of financing: the public sector (including universities) and the private sector [3]. Immunobiologicals have a great impact on prophylaxis and reduced mortality in diseases caused by infection, especially for the needy population who do not have access to health services. Thus, TT is one of the strategies for a country to have access to technology to produce these drugs more quickly to serve the population [4,5]. In this way, this work allowed us to propose a model in order to subsidize evenly a TT methodology for the formulation of production processes. Introduction The pharmaceutical industry generates approximately US $ 1.3 trillion in drug production. It invests hard in research and development, innovation, marketing and distribution of medicines, which run through serums, vaccines and medicines in order to treat public health problems [1]. In this process, several technologies are used and, in order to accelerate business and innovations, pharmaceutical companies use technology transfer (TT) as a process to strengthen the development of new drugs [2,3]. TT is defined as “a logical procedure that controls the transfer of any product along